Condition: Small Cell Lung Carcinoma · Neuroendocrine Neoplasms · Extra-pulmonary Neuroendocrine Carcinoma · Sponsor: Boehringer Ingelheim
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 (also called obrixtamig) that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. The study has 3 parts. In Part 1, participants are put into 2 groups randomly, which means by chance. Participants have an equal chance of being in either group. One group gets dose 1 of BI 764532 and the other group gets dose 2 of BI 764532. In Part 2 and Part 3, all participants receive the same dose of BI 764532. Part 2 and Part 3 are open to people with a certain kind of tumour called extrapulmonary neuroendocrine carcinoma. All participants receive BI 764532 as an infusion into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include an overnight stay to monitor participants´ safety. Doctors record any unwa…
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| Infirmary Cancer Care | Mobile, Alabama, United States | Recruiting |
| Mayo Clinic-Arizona | Phoenix, Arizona, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Mayo Clinic Cancer Center | Jacksonville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Completed |
| University of Kansas Cancer Center | Westwood, Kansas, United States | Completed |
| University of Kentucky Medical Center | Lexington, Kentucky, United States | Recruiting |
| University of Maryland School of Medicine | Baltimore, Maryland, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Completed |
+ 47 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05882058